NeuroVive Pharmaceutical ABのRSI
NeuroVive Pharmaceutical ABのRSIは何ですか。
NeuroVive Pharmaceutical ABのRSIは48.02です。
RSIの定義は何ですか。
相対力指数 (The relative strength index, RSI 14)は、一定期間における損益の規模を比較して、証券の価格変動の速度と変動を測る指標です。
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
LSEのセクタMiscellaneousにおけるRSIの企業と比べるNeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical ABは何をしますか。
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
NeuroVive Pharmaceutical ABと類似のrsi
- AND International Publishers NVのRSIは48.01です。
- AXISCADES Engineering TechnologiesのRSIは48.01です。
- Orchid Island Capital IncのRSIは48.01です。
- Tandy Leather FactoryのRSIは48.01です。
- Bruker CorpのRSIは48.01です。
- Johnson Service PlcのRSIは48.01です。
- NeuroVive Pharmaceutical ABのRSIは48.02です。
- Douglas Dynamics IncのRSIは48.03です。
- E-Tech ResourcesのRSIは48.03です。
- Silver One ResourcesのRSIは48.03です。
- Eastern BanksharesのRSIは48.03です。
- Sastasundar VenturesのRSIは48.03です。
- Golden Path AcquisitionのRSIは48.03です。